Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Timelines and Catalysts
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(93)
•••
Post by MasterAlgaeon Aug 12, 2021 12:19pm
203 Views
Post# 33694341

Timelines and Catalysts

Timelines and Catalysts
So it looks like a re-do of phase II
Find the lowest dose based on WOMAC vs placebo
Apply for fast-track for opioid replacement, get a name for it.
Start phase I for 352
 
Time to result readout for the two trials above 12 to 18months - Is that too optimistic?
 
Catalysts will be results and the anticipation of results. What else?
I doubt that any buyout of anything will be on the table now.
Maybe Antibe will morph into different products in-other-words diversify from just hydrogen sulfide?
Perhaps expand into creating better bio-availability for anti-oxidative supplements and vitamins? That is a huge market. I'll give them that idea for free - lol.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities